STOCK TITAN

Apellis Pharmace - APLS STOCK NEWS

Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.

Apellis Pharmaceuticals, Inc. (APLS) is a leader in developing transformative therapies targeting the complement system, with approved treatments for geographic atrophy and rare blood disorders. This page provides investors and researchers with essential updates on the company’s progress in retinal, hematologic, and renal disease innovation.

Access timely announcements including FDA decisions, clinical trial results, and strategic partnerships that demonstrate Apellis’ commitment to advancing complement immunotherapy. Our curated news collection covers critical developments such as SYFOVRE’s commercial adoption, EMPAVELI’s clinical applications, and research collaborations expanding therapeutic pipelines.

Key updates include regulatory milestones in ophthalmology, hematology treatment expansions, and nephrology research advancements. Bookmark this page to stay informed about Apellis’ pioneering work in C3-targeted therapies and its impact on addressing diseases with limited treatment options.

Rhea-AI Summary
Apellis Pharmaceuticals announces corporate restructuring to drive growth of SYFOVRE and EMPAVELI, with anticipated cost savings of up to $300 million through 2024. SYFOVRE generates $85.7 million in U.S. net product revenues in H1 2023. Workforce reduction of approximately 25% and elimination of planned external expenses. Decision on regulatory approval for SYFOVRE in the EU expected in early 2024. Top-line data from Phase 3 VALIANT study for systemic pegcetacoplan expected in 2024. Prioritizing research initiatives in retina and CNS diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.4%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals provides update on injection kits and events of retinal vasculitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.17%
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals approves grant of equity awards to 13 new employees, with each employee receiving 23,015 restricted stock units (RSUs). RSUs will vest annually based on continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
Rhea-AI Summary
Apellis Pharmaceuticals announced its second quarter 2023 financial results and business highlights. They reported total U.S. net product revenues of $89.6 million, including $67.3 million for SYFOVRE and $22.3 million for EMPAVELI. SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30. Investigation on recently reported rare safety events with SYFOVRE found no indication of drug product or manufacturing issues. Cash and cash equivalents were $616.3 million as of June 30, 2023, with expected cash runway into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.58%
Tags
-
Rhea-AI Summary
Apellis Pharmaceuticals announces positive data from the GALE extension study of SYFOVRE in the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham. Safety profile of SYFOVRE was consistent with previous clinical data. Data presented at the ASRS Annual Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Apellis Pharmaceuticals provides an update on rare events of retinal vasculitis associated with SYFOVRE, a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Seven total events of retinal vasculitis have been confirmed since launch, with no indication of drug product or manufacturing issues contributing to these events. No events were reported in clinical trials. Apellis continues to prioritize patient safety and collaborate with the retina community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (APLS) to discuss second quarter 2023 financial results in conference call and webcast. Investors can access live call and webcast through company website. Replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
Apellis Pharmace

Nasdaq:APLS

APLS Rankings

APLS Stock Data

2.28B
107.71M
13.86%
103.5%
16.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM